Q-omics provides the consensus-scored ATP5MGP4 profile across patient tissues and cancer cell-line models. ATP5MGP4 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, ATP5MGP4 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, ATP5MGP4 RNA expression shows 9,876 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight CHOL, COAD, and LUAD as cancer lineages where ATP5MGP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP5MGP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP5MGP4 survival associations across molecular data types. ATP5MGP4 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP5MGP4 RNA expression–survival associations across cancer types. High ATP5MGP4 expression shows unfavorable associations in CHOL, ACC, KIRP and SARC, but favorable associations in BLCA and LUSC. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for ATP5MGP4 RNA expression.
This table summarizes ATP5MGP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ATP5MGP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP5MGP4 shows lower tumor expression in THCA and KIRC and higher tumor expression in COAD and PRAD. The COAD box plot shows higher ATP5MGP4 RNA expression in tumor versus normal tissue (log2 FC = +0.390, t-test p < 0.001).
This table shows molecular features associated with ATP5MGP4 in patient tissues and cancer cell lines. In patient samples, ATP5MGP4 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
